• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

β受体阻滞剂与肺癌患者生存：荟萃分析。

Beta-blocker and survival in patients with lung cancer: A meta-analysis.

机构信息

Department of Respiratory and Critical Care Medicine, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

Department of Endocrinology and Metabolism, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

出版信息

PLoS One. 2021 Feb 16;16(2):e0245773. doi: 10.1371/journal.pone.0245773. eCollection 2021.

DOI:10.1371/journal.pone.0245773
PMID:33592015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7886135/
Abstract

BACKGROUND

Beta-blocker (BB) is suggested to have anticancer efficacy. However, the potential influence of BB use on overall survival (OS) in patients with lung cancer remains undetermined. We aimed to evaluate the above relationship in an updated meta-analysis.

METHODS

Observational studies comparing OS between users and non-users of BB with lung cancer were identified by search of PubMed, Embase, and Cochrane's Library. A random-effect model was used to pool the results.

RESULTS

Ten retrospective cohort studies with 30870 patients were included. Overall, BB use was not associated with significantly improved OS in lung cancer (hazard ratio [HR] = 1.02, 95% confidence interval [CI]: 0.98 to 1.06, p = 0.33) with moderate heterogeneity (I2 = 29%). Stratified analyses showed similar results in patients with non-small cell lung cancer and small cell lung cancer, in studies with BB use before and after the diagnosis of lung cancer, and in studies with or without adjustment of smoking. Use of BB was associated with improved OS in patients with stage III lung cancer (HR = 0.91, 95% CI: 0.85 to 0.98, p = 0.02) and in patients that did not receive surgery resection (HR = 0.78, 95% CI: 0.64 to 0.96, p = 0.02), while use of non-selective BB was associated with worse OS (HR = 1.14, 95% CI: 1.01 to 1.28, p = 0.03).

CONCLUSIONS

This meta-analysis of retrospective cohort studies does not support a significant association between BB use and improved OS in lung cancer.

摘要

背景

β受体阻滞剂（BB）具有抗癌作用。然而，BB 使用对肺癌患者总生存（OS）的潜在影响仍不确定。我们旨在通过更新的荟萃分析来评估上述关系。

方法

通过检索 PubMed、Embase 和 Cochrane 图书馆，确定了比较 BB 使用与肺癌患者 OS 的观察性研究。使用随机效应模型汇总结果。

结果

纳入了 10 项回顾性队列研究，共 30870 例患者。总体而言，BB 使用与肺癌患者的 OS 改善无关（风险比[HR] = 1.02，95%置信区间[CI]：0.98 至 1.06，p = 0.33），异质性中等（I2 = 29%）。分层分析显示，在非小细胞肺癌和小细胞肺癌患者、BB 使用在肺癌诊断前后的研究、以及有或无吸烟调整的研究中，结果相似。BB 使用与 III 期肺癌患者的 OS 改善相关（HR = 0.91，95%CI：0.85 至 0.98，p = 0.02）和未接受手术切除的患者（HR = 0.78，95%CI：0.64 至 0.96，p = 0.02），而使用非选择性 BB 与较差的 OS 相关（HR = 1.14，95%CI：1.01 至 1.28，p = 0.03）。

结论

本荟萃分析回顾性队列研究不支持 BB 使用与肺癌患者 OS 改善之间存在显著关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/6438d046eb0c/pone.0245773.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/b57376a72d31/pone.0245773.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/38ac9be39c2e/pone.0245773.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/10406962d85b/pone.0245773.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/891720942ab0/pone.0245773.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/cf159d5801ee/pone.0245773.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/8384e2425387/pone.0245773.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/30334fa06144/pone.0245773.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/72f7b1ed230e/pone.0245773.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/6438d046eb0c/pone.0245773.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/b57376a72d31/pone.0245773.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/38ac9be39c2e/pone.0245773.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/10406962d85b/pone.0245773.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/891720942ab0/pone.0245773.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/cf159d5801ee/pone.0245773.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/8384e2425387/pone.0245773.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/30334fa06144/pone.0245773.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/72f7b1ed230e/pone.0245773.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4656/7886135/6438d046eb0c/pone.0245773.g009.jpg

相似文献

1
Beta-blocker and survival in patients with lung cancer: A meta-analysis.β受体阻滞剂与肺癌患者生存：荟萃分析。
PLoS One. 2021 Feb 16;16(2):e0245773. doi: 10.1371/journal.pone.0245773. eCollection 2021.
2
β-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis.β受体阻滞剂的使用与乳腺癌女性临床结局的改善无关：一项荟萃分析。
Biosci Rep. 2020 Jun 26;40(6). doi: 10.1042/BSR20200721.
3
Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.在接受根治性放疗的非小细胞肺癌患者中，偶然使用β受体阻滞剂可改善生存结局。
Ann Oncol. 2013 May;24(5):1312-9. doi: 10.1093/annonc/mds616. Epub 2013 Jan 8.
4
Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer?β受体阻滞剂疗法能否提高转移性非小细胞肺癌患者的生存率？
Asian Pac J Cancer Prev. 2013;14(10):6109-14. doi: 10.7314/apjcp.2013.14.10.6109.
5
Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies.维持治疗改善晚期非小细胞肺癌患者的生存结局：14项研究的荟萃分析
Lung. 2015 Oct;193(5):805-14. doi: 10.1007/s00408-015-9758-y. Epub 2015 Jun 29.
6
Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.以氨柔比星为基础的方案作为广泛期小细胞肺癌一线治疗的疗效和安全性：一项随机对照试验的荟萃分析
Asia Pac J Clin Oncol. 2018 Apr;14(2):e81-e87. doi: 10.1111/ajco.12778. Epub 2017 Oct 25.
7
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.免疫检查点抑制剂与化疗治疗晚期非小细胞肺癌的比较分析：一项随机对照试验的荟萃分析
Medicine (Baltimore). 2018 Aug;97(33):e11936. doi: 10.1097/MD.0000000000011936.
8
Effect of beta-blockers on survival of lung cancer patients: a systematic review and meta-analysis.β受体阻滞剂对肺癌患者生存的影响：系统评价和荟萃分析。
Eur J Cancer Prev. 2020 Jul;29(4):306-314. doi: 10.1097/CEJ.0000000000000544.
9
Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation.β受体阻滞剂可改善多发性骨髓瘤患者的生存结局：一项回顾性评估。
Am J Hematol. 2017 Jan;92(1):50-55. doi: 10.1002/ajh.24582. Epub 2016 Nov 18.
10
Gefitinib for advanced non-small cell lung cancer.吉非替尼用于治疗晚期非小细胞肺癌。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD006847. doi: 10.1002/14651858.CD006847.pub2.

引用本文的文献

1
Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers.普萘洛尔在癌症治疗中起作用吗？对β受体阻滞剂的流行病学和临床试验文献的系统评价。
J Cancer Res Clin Oncol. 2025 Jul 12;151(7):212. doi: 10.1007/s00432-025-06262-2.
2
The Impact of Beta Blockers on Survival in Cancer Patients: A Systematic Review and Meta-Analysis.β受体阻滞剂对癌症患者生存的影响：一项系统评价和荟萃分析
Cancers (Basel). 2025 Apr 18;17(8):1357. doi: 10.3390/cancers17081357.
3
Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension.

本文引用的文献

1
The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.β受体阻滞剂对免疫检查点抑制剂治疗非小细胞肺癌患者生存结局的影响。
Clin Lung Cancer. 2021 Jan;22(1):e57-e62. doi: 10.1016/j.cllc.2020.07.016. Epub 2020 Aug 5.
2
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline Summary.根治性意向性治疗后的肺癌监测：美国临床肿瘤学会指南摘要
JCO Oncol Pract. 2020 Feb;16(2):83-86. doi: 10.1200/JOP.19.00722. Epub 2020 Jan 9.
3
A systematic review of survival following anti-cancer treatment for small cell lung cancer.
高血压的结直肠癌、肺癌、子宫体癌、黑色素瘤和肾癌患者诊断后使用抗高血压药物与生存情况
BMC Cancer. 2025 Jan 8;25(1):38. doi: 10.1186/s12885-024-13273-8.
4
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.心力衰竭药物治疗与癌症：相关途径和临床前/临床证据。
Eur Heart J. 2024 Apr 7;45(14):1224-1240. doi: 10.1093/eurheartj/ehae105.
5
Lung cancer associated with combustion particles and fine particulate matter (PM) - The roles of polycyclic aromatic hydrocarbons (PAHs) and the aryl hydrocarbon receptor (AhR).与燃烧颗粒和细颗粒物 (PM) 相关的肺癌 - 多环芳烃 (PAHs) 和芳香烃受体 (AhR) 的作用。
Biochem Pharmacol. 2023 Oct;216:115801. doi: 10.1016/j.bcp.2023.115801. Epub 2023 Sep 9.
6
Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer.β受体阻滞剂的使用与头颈部癌症患者无复发生存率的降低相关。
JCO Precis Oncol. 2023 Jun;7:e2200490. doi: 10.1200/PO.22.00490.
7
Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems.药物再利用治疗非小细胞肺癌：旧方案应对新问题。
Curr Oncol. 2023 Jan 5;30(1):704-719. doi: 10.3390/curroncol30010055.
8
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.抗糖尿病药、驱虫药、他汀类药物和β-受体阻滞剂作为癌症治疗的辅助药物。
Medicina (Kaunas). 2022 Sep 7;58(9):1239. doi: 10.3390/medicina58091239.
9
Neuroimmune crosstalk and its impact on cancer therapy and research.神经免疫相互作用及其对癌症治疗和研究的影响。
Discov Oncol. 2022 Aug 23;13(1):80. doi: 10.1007/s12672-022-00547-5.
10
Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis.β肾上腺素能受体阻滞剂与肝细胞癌生存：系统评价和荟萃分析。
Clin Exp Med. 2023 Jul;23(3):853-858. doi: 10.1007/s10238-022-00842-z. Epub 2022 Jun 23.
小细胞肺癌抗癌治疗后生存情况的系统评价。
Lung Cancer. 2020 Mar;141:44-55. doi: 10.1016/j.lungcan.2019.12.015. Epub 2020 Jan 11.
4
Real-world guideline-based treatment of lung cancer improves short- and long-term outcomes and resection rate: A population-based study.基于真实世界指南的肺癌治疗可改善短期和长期结局及切除率：一项基于人群的研究。
Lung Cancer. 2020 Feb;140:1-7. doi: 10.1016/j.lungcan.2019.12.002. Epub 2019 Dec 4.
5
Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients.兰地洛尔，一种超短效β1受体阻滞剂，用于预防肺癌术后复发：一项III期、多中心、两组平行患者随机试验的研究方案。
Trials. 2019 Dec 11;20(1):715. doi: 10.1186/s13063-019-3904-4.
6
β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers.β-肾上腺素能信号在肺癌中的作用：β-受体阻滞剂的潜在作用。
J Neuroimmune Pharmacol. 2020 Mar;15(1):27-36. doi: 10.1007/s11481-019-09891-w. Epub 2019 Dec 11.
7
Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy.肿瘤免疫学与免疫治疗中的β-肾上腺素能信号传导
Crit Rev Immunol. 2019;39(2):93-103. doi: 10.1615/CritRevImmunol.2019031188.
8
Beta-Blocker Use and Lung Cancer Mortality in a Nationwide Cohort Study of Patients with Primary Non-Small Cell Lung Cancer.一项针对原发性非小细胞肺癌患者的全国性队列研究中β受体阻滞剂的使用与肺癌死亡率
Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):119-126. doi: 10.1158/1055-9965.EPI-19-0710. Epub 2019 Oct 22.
9
Effect of beta-blockers on survival of lung cancer patients: a systematic review and meta-analysis.β受体阻滞剂对肺癌患者生存的影响：系统评价和荟萃分析。
Eur J Cancer Prev. 2020 Jul;29(4):306-314. doi: 10.1097/CEJ.0000000000000544.
10
Effects of β-Adrenergic Antagonists on Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.β-肾上腺素能拮抗剂对局部晚期非小细胞肺癌放化疗的影响
J Clin Med. 2019 Apr 26;8(5):575. doi: 10.3390/jcm8050575.